Capstone Asset Management Co. Sells 1,318 Shares of Eli Lilly and Company (LLY)
Capstone Asset Management Co. decreased its position in Eli Lilly and Company (NYSE:LLY) by 1.3% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 102,345 shares of the company’s stock after selling 1,318 shares during the quarter. Capstone Asset Management Co.’s holdings in Eli Lilly and were worth $8,423,000 at the end of the most recent quarter.
Other large investors have also recently modified their holdings of the company. Heritage Trust Co acquired a new stake in Eli Lilly and in the first quarter valued at approximately $135,000. Point72 Asia Hong Kong Ltd grew its position in Eli Lilly and by 237.4% in the first quarter. Point72 Asia Hong Kong Ltd now owns 1,761 shares of the company’s stock valued at $148,000 after acquiring an additional 1,239 shares in the last quarter. Penserra Capital Management LLC grew its position in Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after acquiring an additional 176 shares in the last quarter. American National Bank grew its position in Eli Lilly and by 5.2% in the second quarter. American National Bank now owns 2,088 shares of the company’s stock valued at $172,000 after acquiring an additional 104 shares in the last quarter. Finally, Sandy Spring Bank grew its position in Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after acquiring an additional 750 shares in the last quarter. 75.77% of the stock is owned by institutional investors.
Shares of Eli Lilly and Company (NYSE:LLY) traded down 0.76% during trading on Friday, reaching $82.44. The company had a trading volume of 5,374,504 shares. The stock has a 50 day moving average price of $80.89 and a 200 day moving average price of $82.06. Eli Lilly and Company has a 12 month low of $64.18 and a 12 month high of $86.72. The firm has a market capitalization of $86.97 billion, a PE ratio of 35.67 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, July 25th. The company reported $1.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.06. The business had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. Eli Lilly and’s quarterly revenue was up 7.8% on a year-over-year basis. During the same period in the previous year, the business posted $0.86 earnings per share. On average, equities research analysts forecast that Eli Lilly and Company will post $4.16 EPS for the current year.
The company also recently disclosed a quarterly dividend, which was paid on Friday, September 8th. Stockholders of record on Tuesday, August 15th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a dividend yield of 2.52%. The ex-dividend date was Friday, August 11th. Eli Lilly and’s dividend payout ratio is presently 90.04%.
Several analysts have issued reports on the stock. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $94.00 price objective for the company in a research report on Monday, July 17th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $93.00 price objective on shares of Eli Lilly and in a research report on Thursday, June 22nd. Deutsche Bank AG reaffirmed a “buy” rating and issued a $91.00 price objective (up previously from $90.00) on shares of Eli Lilly and in a research report on Monday, July 17th. Morgan Stanley reaffirmed a “hold” rating and issued a $86.00 price objective on shares of Eli Lilly and in a research report on Friday. Finally, Berenberg Bank reaffirmed a “buy” rating and issued a $100.00 price objective on shares of Eli Lilly and in a research report on Thursday, July 27th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly and presently has an average rating of “Hold” and an average price target of $88.27.
In other news, major shareholder Lilly Endowment Inc sold 220,000 shares of the business’s stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the sale, the insider now directly owns 124,049,283 shares in the company, valued at $10,307,254,924.47. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last 90 days, insiders have sold 825,000 shares of company stock worth $68,456,650. 0.20% of the stock is currently owned by company insiders.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Stock Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related stocks with our FREE daily email newsletter.